The site uses anonymous third party analytic cookies: in accessing any element/area of the site outside of this banner, you consent to receiving cookies.

Dillon warns of ‘startling costs’ of medical innovation

single--2

Will the costs of medical innovation impact NHS budgets?

 

The boss of the drug watchdog has warned the NHS faces a challenge to fund new medical technology.

 

Sir Andrew Dillon, chief executive of the National Institute for Health and Care Excellence (NICE), has spoken of the ‘startling costs’ associated with medical innovation and how they provided a challenge to fund new personalised drugs.

 

Speaking to the Health Service Journal (HSJ), he said the position suggested the need in future for different models of funding for effective high-cost drugs; that there would be more interest in NICE guidelines from national leaders; and there could be health service capacity issues with tighter budgets and more demand.

 

He added that a new resource impact panel has been established with representatives from NHS England, NHS Improvement and Public Health England, to look at new NICE guidelines which will have a ‘substantial net resource impact’.

 

Further information

HSJ: NICE chief: NHS faces ‘startling costs’ from new treatments